#Iceland #Reykjavik #Embla Medical #Streifeneder #orthopedic solutions

Embla Medical Enhances Presence in Orthopedic Market with New Investment

On July 17, 2025, Embla Medical, a prominent provider of innovative mobility solutions, announced its strategic decision to invest in a majority share of 51% in Streifeneder ortho.production GmbH. This acquisition marks a notable step in Embla's mission to broaden its reach in the orthopedic sector, particularly in Germany, which represents the second-largest orthopedic market globally.

Details of the Transaction

Embla Medical, listed on NASDAQ Copenhagen (EMBLA), is committed to improving people's mobility. The agreement with Streifeneder ortho.production, a subsidiary of Streifeneder KG based in Bayern, Germany, signifies an exciting opportunity for Embla to strengthen its product portfolio. Streifeneder is renowned for developing and supplying orthopedic mobility solutions, including prosthetic and orthotic components, along with orthopedic materials and equipment used in surgery.

In 2024, Streifeneder reported an impressive revenue of €25 million (around USD 29 million), with approximately 70% stemming from sales related to prosthetics and orthopedic materials. Most of this business is generated in Germany, with significant sales also occurring in other key European markets and a presence extending into the Americas and Asia Pacific (APAC).

By acquiring a majority stake in Streifeneder, Embla Medical aims to establish itself as a comprehensive provider in the orthopedic market. The investment is expected to facilitate growth, aligning with Embla's 'Growth'27 strategy and positioning the company to reach a larger patient demographic with a wider array of products.

Strategic Insights

Sveinn Sölvason, President and CEO of Embla Medical, expressed optimism regarding this venture, stating, "The investment in Streifeneder is a strong strategic fit with our Growth'27 strategy and will enable us to reach more patients with a broader product offering." Sölvason believes that this collaboration will enhance Embla's presence in key markets while also opening gates to emerging markets.

Friedrich Streifeneder, the Managing Director of Streifeneder ortho.production, echoed these sentiments, noting, "By joining forces with Embla Medical, we have found the ideal partner for Streifeneder. The combination of our businesses will secure a strong position in the orthopedic market with a significant value offering." This partnership is expected to elevate customer experiences by integrating the strengths of both Embla and Streifeneder.

Future Prospects

The deal is subject to regulatory approvals, but it presents promising growth prospects for both companies. The global prosthetics market is anticipated to grow between 5-7% in the coming years, which aligns with Streifeneder's projected growth. Furthermore, by leveraging Embla Medical and Össur's expansive global footprint, the partnership is set to realize commercial synergies that can benefit a broader audience.

As part of the transaction, Embla Medical plans to issue 2,805,135 new shares to raise capital for the acquisition, reflecting a nominal increase in share capital by about 0.7%. The sellers of Streifeneder will subscribe to all new shares, committing to a two-year lock-up period following the deal completion.

Conclusion

In summary, Embla Medical’s investment in Streifeneder ortho.production signifies a strategic maneuver to amplify its influence in the orthopedic solutions market. As the company embarks on this new journey, it aims to enhance patient engagement and expand its product range, adhering to their commitment to innovation in mobility solutions. As operational aspects unfold, the industry eagerly watches this partnership yield advancements in orthopedic healthcare across various regions.